Immunology
Page 1 • 12 itemsGain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study
InflaRx reports favorable safety data for Izicopan showing low reactive metabolite formation in human liver microsomes, reducing bioactivation risks.
InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study
InflaRx announces positive pre-clinical data showing low reactive metabolite formation for izicopan in human liver microsomes, supporting drug safety profile.
UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal
UCB's acquisition of Candid Therapeutics strengthens autoimmune pipeline as Two River and Vida Ventures celebrate successful exit from clinical-stage biotech.
NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment
Australia's TGA approves NIKTIMVO (axatilimab), a breakthrough first-in-class therapy for chronic graft-versus-host disease under priority review.
Atara Biotherapeutics Receives FDA Complete Response Letter for EBVALLO Cancer Treatment, Faces Securities Class Action
Atara Biotherapeutics' EBVALLO cancer therapy receives FDA Complete Response Letter, delaying approval as company faces securities class action lawsuit deadline May 22, 2026.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood disorders and GVHD patients.
MRM Health's MH002 Receives FDA Fast Track Designation for Ulcerative Colitis Treatment
MRM Health's lead microbiome therapeutic MH002 granted FDA Fast Track status for mild-to-moderate ulcerative colitis, accelerating development timeline.
Cadrenal Therapeutics CAD-1005 Gets FDA Guidance for Phase 3 Trial in Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics receives FDA guidance to advance CAD-1005 to Phase 3 for HIT after Phase 2 showed 25% reduction in blood clots when added to standard care.
RedHill's RHB-204 Shows Comparable Efficacy to RHB-104 in Crohn's Disease MAP Treatment Development
RedHill's next-generation RHB-204 demonstrates comparable MAP-killing efficacy to RHB-104, advancing development for Crohn's disease treatment.
IgA Nephropathy Market to Reach New Heights by 2036 as Novartis Zigakibart and Novel Immunotherapies Drive Growth
IgA nephropathy market expansion driven by Novartis Zigakibart, Roche Sefaxersen, and emerging immunotherapies through 2036 with improved patient outcomes.
Regeneron Q1 2026 Earnings: Dupixent Sales Surge 33% to $4.9B, EYLEA HD Shows Strong Growth
Regeneron reports 19% revenue growth to $3.6B in Q1 2026, driven by Dupixent's 33% sales increase to $4.9B and EYLEA HD's 52% growth to $468M.
Teva's PONLIMSI Biosimilar Receives FDA Approval for All Prolia Indications as Q1 2026 Results Show Strong Growth
Teva's PONLIMSI biosimilar gains FDA approval for all Prolia indications while duvakitug shows promising Phase 2b results in inflammatory bowel disease.